You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
-
Towards a New Generation of Glycoengineered Pneumococcal Bioconjugate Vaccines
SBC: VaxNewMO Topic: NIAIDPROJECT SUMMARY Pneumococcal conjugate vaccines (PCVs), composed of a pneumococcal polysaccharide covalently linked to a carrier protein, are life-saving prophylactics used to prevent pneumococcal disease. Importantly, PCVs provide immunity for all age groups, including, infants and children under the age of two, which is not the case for purely polysaccharide vaccines. Like all conjugate vaccines ...
SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health -
FoxWare™, An Advanced Data Analysis Package for Hydroxyl Radical Foot-Printing Higher Order Structural Analysis
SBC: GENNEXT TECHNOLOGIES, INC. Topic: 300The GenNext Phase II SBIR submssion entitled “FoxWare™, an Advanced Data Analysis Package for Hydroxyl Radical Foot-printing Higher Order Structural Analysis” is responsive to the ackowledged need for new and improved tools for higher order structural analysis (HOS) of biopharmaceuticals. Biopharmaceuticals are complex, heterogeneous mixtures of 3-dimensional biomolecules, whose safety and e ...
SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health -
Therapeutic UV Disinfection System to Prevent Catheter Related Bloodstream Infections (CRBSIs) in Patients with Peripherally Inserted Central Catheters (PICCs)
SBC: Puracath Medical, INc Topic: NIAIDAbstract PuraCath’s goal with the Phase II SBIR is to develop an FDA-approved therapeutic system for disinfection of a needleless connector (NC) for Peripherally Inserted Central Catheters (PICC) that reduces the risk of intraluminal colonization as a source of catheter-related blood stream infections (CRBSI). More specifically, it utilizes Ultraviolet (UV) light to eliminate microbes and biofil ...
SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health -
Bone targeted delivery of an antimicrobial drug for osteomyelitis therapy
SBC: BIOVINC, LLC Topic: NIAIDABSTRACTIn general, the incidence of osteomyelitis is around 1-2% in patients undergoing total knee and hip replacement surgeries. When patients have to undergo revision therapy to replace infected implants, mortality is 18%. Due to the aging of the population in the US, and the increase in the number of total joint arthroplasties in this population, the annual cost of infected revision surgeries ...
SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health -
Strain-Independent Therapeutic Antibodies for Influenza
SBC: TRELLIS BIOSCIENCE, INC. Topic: NIAIDSUMMARY In this Phase IIB proposal, we seek funding to complete the IND-enabling development of CF-404, a mixture of three native human monoclonal antibodies (mAbs). Activity has been established in mouse models against representatives of all major circulating strains of influenza A and B. By providing a pan-influenza treatment, we avoid delays associated with strain typing, with improved outcomes ...
SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health -
Bloodstream infection detection directly on whole blood
SBC: SCANOGEN INC. Topic: NIAIDBloodstream infection detection directly on whole blood Summary Sepsis is a life-threatening condition triggered by the presence of fungi or bacteria in the bloodstream that affects 1.3 million people each year in the United States.1 Rapid antimicrobial administration is critical for sepsis treatment.2-4 However, the current gold standard for bloodstream infection diagnosis is blood culture (BC), ...
SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health -
Pre-IND Development of an Arenavirus Antiviral
SBC: Arisan Therapeutics, Inc. Topic: NIAIDSummary Arenaviruses comprise a diverse family. Several species are associated with severe arenaviral hemorrhagic fever (AVHF) in humans that exhibit case-fatality rates as high as 30%. Human infection with arenaviruses typically occurs through contact with materials contaminated with the excretions of an infected rodent although direct human- to-human transmission may occur in clinical settings. ...
SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health -
Rapid quantification of nuclear citrullination in human neutrophils
SBC: Epicypher, Inc. Topic: NIAIDPROJECT SUMMARYChromatin structure and gene expression are controlled by histone post-translational modifications (PTMs) on nucleosomes, the basic repeating unit of chromatin. Chromatin decondensation is controlled in part by the PAD4-dependent conversion of arginine to citrulline on histones (i.e. citrullination). Significantly, PAD4 activation in neutrophils initiates a cell death program distin ...
SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health -
Pre-clinical development of SPY-DYS45-55, a CRISPR/Cas9 platform for Duchenne muscular dystrophy
SBC: Myogene Bio LLC Topic: NIAMSMyoGene Bio is a startup dedicated to developing cutting edge genetic therapies for muscle diseases. In this proposal, the company will advance development of our potential therapeutic, SPY-DYS45-55, a CRISPR/Cas9 gene editing platform for Duchenne muscular dystrophy (DMD) in conjunction with research partners at UCLA. Duchenne is a devastating muscle wasting disorder with no cure that is caused b ...
SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health -
A Vaccine for Schistosomiasis, "SchistoShield"
SBC: PAI Life Sciences, Inc. Topic: NIAIDPROJECT SUMMARY Schistosomiasis is a major parasitic disease which could impact up to a billion people in 74 countries. Current control strategies rely primarily on anti-parasitic drugs alone (praziquantel) which has proven inadequate due to both reinfection and the inherent threat of drug resistance. We have developed a potent schistosomiasis vaccine, termed SchistoShield®, targeting a functiona ...
SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health